| Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study AS Omrani, MM Saad, K Baig, A Bahloul, M Abdul-Matin, AY Alaidaroos, ... The Lancet Infectious Diseases 14 (11), 1090-1095, 2014 | 624 | 2014 |
| Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia M Saad, AS Omrani, K Baig, A Bahloul, F Elzein, MA Matin, MAA Selim, ... International journal of infectious diseases 29, 301-306, 2014 | 559 | 2014 |
| Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection VM Corman, AM Albarrak, AS Omrani, MM Albarrak, ME Farah, M Almasri, ... Clinical Infectious Diseases 62 (4), 477-483, 2016 | 458 | 2016 |
| Tocilizumab for the treatment of severe coronavirus disease 2019 R Alattar, TBH Ibrahim, SH Shaar, S Abdalla, K Shukri, JN Daghfal, ... Journal of medical virology 92 (10), 2042-2049, 2020 | 293 | 2020 |
| COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) L Pagano, J Salmanton-García, F Marchesi, A Busca, P Corradini, ... Journal of hematology & oncology 14 (1), 168, 2021 | 264 | 2021 |
| A family cluster of Middle East respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case AS Omrani, MA Matin, Q Haddad, D Al-Nakhli, ZA Memish, AM Albarrak International Journal of Infectious Diseases 17 (9), e668-e672, 2013 | 214 | 2013 |
| Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta‐analysis ME Morra, L Van Thanh, MG Kamel, AA Ghazy, AMA Altibi, LM Dat, ... Reviews in medical virology 28 (3), e1977, 2018 | 201 | 2018 |
| Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction AS Omrani, JA Al-Tawfiq, ZA Memish Pathogens and global health 109 (8), 354-362, 2015 | 186 | 2015 |
| Middle East respiratory syndrome coronavirus (MERS-CoV): what lessons can we learn? AS Omrani, S Shalhoub Journal of hospital infection 91 (3), 188-196, 2015 | 119 | 2015 |
| Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 AS Omrani, SA Pathan, SA Thomas, TRE Harris, PV Coyle, CE Thomas, ... EClinicalMedicine 29, 2020 | 91 | 2020 |
| Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients GA Almekhlafi, MM Albarrak, Y Mandourah, S Hassan, A Alwan, ... Critical Care 20, 1-9, 2016 | 84 | 2016 |
| Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review A Soriano, Y Carmeli, AS Omrani, LSP Moore, M Tawadrous, P Irani Infectious diseases and therapy 10, 1989-2034, 2021 | 77 | 2021 |
| Clinical characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative bacteria from critically ill patients with COVID-19 A Baiou, AA Elbuzidi, D Bakdach, A Zaqout, KM Alarbi, AA Bintaher, ... Journal of Hospital Infection 110, 165-171, 2021 | 71 | 2021 |
| Physicians’ knowledge, perceptions, and attitudes toward antimicrobial prescribing in Riyadh, Saudi Arabia AM Baadani, K Baig, WA Alfahad, S Aldalbahi, AS Omrani Saudi medical journal 36 (5), 613, 2015 | 66 | 2015 |
| Prevalence of colistin and tigecycline resistance in Acinetobacter baumannii clinical isolates from 2 hospitals in Riyadh Region over a 2-year period AM Baadani, SI Thawadi, NA El-Khizzi, AS Omrani Saudi Med J 34 (3), 248-253, 2013 | 61 | 2013 |
| First report of Candida auris infections from Saudi Arabia B Abdalhamid, R Almaghrabi, S Althawadi, A Omrani Journal of Infection and Public Health 11 (4), 598-599, 2018 | 59 | 2018 |
| High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia AS Omrani, WA Alfahad, MM Shoukri, AM Baadani, S Aldalbahi, ... Annals of clinical microbiology and antimicrobials 14, 1-6, 2015 | 59 | 2015 |
| The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study AS Omrani, MA Almaslamani, J Daghfal, RA Alattar, M Elgara, SH Shaar, ... BMC infectious diseases 20, 1-11, 2020 | 47 | 2020 |
| Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report AS Omrani, A Zaqout, A Baiou, J Daghfal, N Elkum, RA Alattar, D Bakdach, ... Journal of Medical Virology 93 (3), 1678-1686, 2021 | 39 | 2021 |
| Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications MAY Al-Nesf, HB Abdesselem, I Bensmail, S Ibrahim, WAH Saeed, ... Nature communications 13 (1), 946, 2022 | 37 | 2022 |
Dr. Ahmed ZaqoutHamad Medical Corporation在 hamad.qa 的电子邮件经过验证
